High-dose Wegovy cuts weight 21%, new data shows
At a time when Novo Nordisk (NOVN: N) has appeared to be slipping behind rival Eli Lilly (NYSE: LLY) and its blockbuster Zepbound (tirzepatide) in the race to be the frontrunner in obesity, the Danish pharma major has fought back with some compelling data on its product Wegovy (semaglutide injection).
The company has presented the results from the Phase IIIb STEP UP trial for weight management in adults with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago.
In the STEP UP trial, a higher, once-weekly 7.2mg dose of Wegovy, demonstrated a mean weight loss of 20.7%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze